IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis.

Weidong Zhu 1,8, Ichiro Shiojima 1,8, Yuzuru Ito 2,8, Zhi Li 1, Hiroyuki Ikeda 1, Masashi Yoshida 1, Atsuhiko T. Naito 1, Jun-ichiro Nishi1, Hiroo Ueno 3, Akihiro Umezawa 4, Tohru Minamino 1, Toshio Nagai 1, Akira Kikuchi 5, Makoto Asashima 2,6,7 & Issei Komuro 1

Source

Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan

ICORP Organ Regeneration Project, Japan Science and Technology Agency (JST), Tokyo 153-8902, Japan

Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA

Department of Reproductive Biology, National Institute for Child Health and Development, Tokyo 157-8535, Japan

Department of Biochemistry, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan

Department of Life Sciences (Biology), Graduate School of Arts and Science, The University of Tokyo, Tokyo 153-8902, Japan

National Institute of Advanced Industrial Sciences and Technology (AIST), Ibaraki 305-8562, Japan

These authors contributed equally to this work.

http://www.ncbi.nlm.nih.gov/pubmed/18528331

http://www.nature.com/nature/journal/v454/n7202/full/nature07027.html

http://www.nature.com/nature/journal/v454/n7202/pdf/nature07027.pdf

ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture and Health and Labor Sciences Research Grants (to I.K.); a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science

and Technology of Japan; and grants from the Suzuken Memorial Foundation,

the Japan Diabetes Foundation, the Ichiro Kanehara Foundation, the Tokyo

Biochemical Research Foundation, the Takeda Science Foundation, the Cell Science

Research Foundation and the Japan Foundation of Applied Enzymology (to T.M.).